Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response to pneumococcal polysaccharide vaccination in healthy adults
2019-001118-40Phase 4Active
- Sponsor
- Department of Pulmonology
- Start
- Aug 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Department of Pulmonology. Primary endpoint: Distribution of baseline serotype-specific IgG titers. Started Aug 2019; status: active.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2019-001118-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001118-40.